Followers | 0 |
Posts | 2177 |
Boards Moderated | 0 |
Alias Born | 04/13/2018 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, July 28, 2020 2:35:18 PM
Humanigen's drug has quickly run through it's trials on account of it's lax standard in it's study criteria. As such it is now in a competition study against Remdesivir where it now faces two lethal pitfalls.
Pitfall 1: Death By Apples And Oranges
Remdesivir and Humanigen's questionable cocktail have both gone through their testing. However Remedsivir's inclusion and exclusion criteria are different from Humanigen. A comparison study done on Humanigen's terms will create an abnormal data set. Remdesivir had more rigorous testing. So having the same light standards as Humanigen will show greater efficacy then what physicians in the field are already seeing. This will raise questions about the legitimacy of the study.
If Humanigen runs under Remdesivir's standards, they will have to include patients they got to exclude under their cherry picking protocols. This means lower efficacy and safety results. As these excluded groups will likely report more adverse reactions.
If Humanigen is allowed to run under it's own cherry picked standards doing a comparison becomes a moot point. Comparing apples to oranges as it were.
Pitfall 2: Safety Results
Humanigen has not fully released all it's safety data, a search on google yielded only the infamous 12 person study. 12 cherry picked patients none of them on oxygen yet declared to be in the severe category:
https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2
So in the competition study more results are to come. If they are on par with or only slightly better than Remdesivir then Humanigen is dead in the water.
Why you ask?
Because another drug has already show itself to be 63% safer. So even if Humanigen breezes by on its lax testing standards it still can't escape it's safety profile. Unless it has a stellar moonshot safety profile they run into another Chagas fiasco and no drug:
https://www.nature.com/articles/nbt1117-1003.pdf?origin=ppub
Do your due diligence, don't get caught in the pump and dump.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM